コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 hols (dopamine, epinephrine, norepinephrine, 3, 4-dihydroxyphenylacetic acid.
4 etaldehyde, a potentially toxic aldehyde, to 3,4-dihydroxyphenylacetic acid, a non toxic metabolite.
5 phenylacetic acid, and further metabolism of 3,4-dihydroxyphenylacetic acid and 4-hydroxyphenylacetic
6 ine (DA) and serotonin and their metabolites 3,4-dihydroxyphenylacetic acid and 5-hydroxyindole aceti
7 omatic L-amino acid decarboxylase, dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid wer
8 d by a decrease in the dopamine metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, as
9 lues reflect rates of dopamine metabolism to 3,4-dihydroxyphenylacetic acid and homovanillic acid, ou
10 r 3,4-dihydroxyphenylalanine, and metabolite 3,4-dihydroxyphenylacetic acid completely block the nitr
11 l in the striatum (~60%), the DA (~22%), and 3,4-dihydroxyphenylacetic acid content (~29%), respectiv
12 rease in the concentration of dopamine (DA), 3, 4-dihydroxyphenylacetic acid (DOPAC), and homovanilli
13 oncentrations of DA and its main metabolite, 3, 4-dihydroxyphenylacetic acid (DOPAC), in the median e
14 for MAO A, but not MAO B, and the levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyra
15 significant increase in both DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
16 sal concentrations of DA or its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
17 ellular levels of DA and the DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
18 pletion of dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
19 20 min after injection while DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
20 exhibited by a loss of DA and DA metabolite [3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
21 leus accumbens, and an increase in dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and serotonin.
22 ed extracellular levels of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) at all doses and
24 tially affects basal and evoked dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in the su
25 f 5-hydroxyindole-3-acetic acid (5-HIAA) and 3,4-dihydroxyphenylacetic acid (DOPAC) from their respec
26 , 5-hydroxyindole-3-acetic acid (5-HIAA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in isolated hamst
27 ntification of DA and its primary metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in mouse retina.
28 ring the concentrations of the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the median emi
31 ole increased concentrations of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) in the paraventri
32 The effects of the synthesized compounds on 3,4-dihydroxyphenylacetic acid (DOPAC) levels correlated
33 ortionally greater depletion of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the str
34 f DA metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) reflected changes
36 of oxidation products of dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid (DOPAC) to inhibit protea
37 tent of dopamine and the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) were measured by
38 nhibition) and metabolism (concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC)) in terminals of
39 taneously to assess changes in ascorbate and 3,4-dihydroxyphenylacetic acid (DOPAC), a major dopamine
40 ere that substoichiometric concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC), a normal product
41 extracellular basal levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and 4-hydroxy-3-
42 bens (NAS), ethanol decreased dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and HVA levels i
43 eased levels of dopamine and its metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), as well as serot
44 hrine, 3,4-dihydroxy-phenylalanine (L-DOPA), 3,4-dihydroxyphenylacetic acid (DOPAC), methyldopamine,
49 dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and ves
50 nificant increase in the levels of dopamine, 3-4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
51 (DA concentrations) and catabolic activity (3,4-dihydroxyphenylacetic acid; DOPAC) of A11 DA neurons
52 helial peptide transporter PepT1 inhibitor), 3,4-dihydroxyphenylacetic acid (dopamine metabolite neur
53 ll as metabolites 5-hydroxyindolacetic acid, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 3
54 riatum and enhanced levels of the metabolite 3,4-dihydroxyphenylacetic acid in frontal cortex and hyp
55 significantly reduced levels of dopamine and 3,4-Dihydroxyphenylacetic acid in the striatum as well a
56 also characterized, including ascorbic acid, 3,4-dihydroxyphenylacetic acid, serotonin, adenosine, an
57 HT should previously be oxidized to DOPAC (3,4-dihydroxyphenylacetic acid) which reacts with MGO by